GLP-1 Peptide Analysis: Chromatography Methods, Impurity Profiling, and Analytical Challenges

GLP-1 peptide analysis is among the most demanding workflows in modern pharmaceutical separation science, because semaglutide, tirzepatide, and related receptor agonists generate dense impurity profiles whose components differ from the parent molecule by only a single oxidation, deletion, or stereochemical inversion. Resolving those species reliably calls for high-efficiency columns, carefully tuned ion-pairing conditions, and orthogonal mass spectrometric confirmation, all held to tightening regulatory expectations.

Why GLP-1 Peptides Defy Small-Molecule Methods

GLP-1 receptor agonists occupy an awkward middle ground between small molecules and large biologics. At thirty to thirty-nine amino acids, they are large enough to fold into secondary structure and to carry hydrophobic acylation chains, yet small enough that analysts often approach them with a small-molecule mindset. In reversed-phase chromatography, the consequence is an adsorption-desorption retention mechanism rather than gradual partitioning, which makes retention unusually sensitive to gradient slope, organic modifier, temperature, and the ion-pairing reagent.

These molecules are also prone to non-specific adsorption on metal surfaces, which degrades peak shape and sensitivity on conventional stainless-steel flow paths. That single behavior explains why so many first attempts at a GLP-1 method produce tailing peaks and irreproducible areas.

Regulatory expectations make this precision non-negotiable. Under the FDA guidance on highly purified synthetic peptides, any new impurity above 0.5 percent in a proposed generic is not acceptable, while impurities between 0.10 percent and 0.5 percent must be identified, characterized, and justified, including for immunogenicity risk. With the first generic GLP-1 peptide, a liraglutide injection, approved in December 2024, every manufacturer pursuing the synthetic pathway now works to that bar.

At a structural level, the difficulty begins with size and conformation. These peptides fold, carry hydrophobic acyl chains, and present several interaction points to the stationary phase at once, which is why their retention behaves so differently from a small molecule. Grasping why peptide size and structure complicate every stage of the separation is the foundation for every method decision that follows.

What Makes GLP-1 Impurity Profiling So Difficult?

The defining challenge of GLP-1 impurity profiling is that the most important impurities are near-perfect structural mimics of the drug. A D-amino acid isomer carries the identical mass and molecular formula as the parent peptide, differing only in the three-dimensional arrangement at a single residue. Oxidation of methionine or tryptophan adds just 16 Da and shifts retention only slightly. Truncations that remove a single residue can elute on the shoulder of the main peak. None of these forgiving separations that small-molecule analysts expect apply here.

The impurities that matter most in a GLP-1 drug are near-perfect copies of the drug itself.

Each class behaves differently at the residue level. A methionine sulfoxide shifts polarity in one direction, while a D-isomer shifts nothing measurable at all, so the separation has to be matched to the specific modification rather than applied uniformly. The residue-by-residue mechanics of resolving these near-identical structural mimics in reversed phase determine which gradient and selectivity choices will actually work. The table below summarizes the principal impurity classes and the strategy each one rewards.

Table 1. GLP-1 impurity classes and recommended analytical approaches

Chromatographic Modes for GLP-1 Peptide Analysis

No single separation mode answers every question about a GLP-1 therapeutic. A robust program layers orthogonal techniques: reversed-phase chromatography as the primary purity and impurity method, ion-pairing to tune selectivity for the most stubborn pairs, size-exclusion chromatography for aggregation, and mass spectrometry for identity and sequence. Treating these as one integrated workflow, rather than separate projects, is what separates a method that survives transfer from one that does not.

Choosing among them is rarely a clean decision. Reversed phase gives the most information per run, but cannot see aggregates, size-exclusion sees aggregates, but not sequence variants, and mass spectrometry confirms identity but depends on a clean upstream separation. Working through the practical trade-offs that shape a GLP-1 chromatography method is where much of the method-development time is spent.

Table 2. Orthogonal separation modes in a GLP-1 analytical workflow

How Do You Choose Columns and Conditions for GLP-1 Methods?

Column efficiency does more work in GLP-1 analysis than in almost any small-molecule assay, because resolution of critical pairs is driven by peak capacity. Core-shell, or superficially porous, particles narrow the diffusion path and sharpen peaks, which improves the resolution of impurities present at trace levels without forcing the method to extreme pressures. Pore size matters as well: a 100 to 160 Å pore generally suits these relatively small peptides better than the 300 Å pore reserved for larger proteins, because it offers more surface area while still avoiding restricted diffusion.

In GLP-1 analysis, column efficiency does more work than in almost any small-molecule assay.

On the mobile-phase side, trifluoroacetic acid remains the default ion-pairing reagent for sharp peaks, with shallow gradients and elevated column temperatures used to coax apart the hardest pairs. Where mass spectrometric compatibility is needed, difluoroacetic acid offers a useful compromise between peak shape and ionization. Metal-free or low-adsorption hardware is increasingly chosen to control the non-specific adsorption that plagues these peptides.

The advantage is thermodynamic rather than incidental. A solid silica core wrapped in a thin porous layer shortens the distance analytes diffuse, which narrows peaks and raises the plate count that trace-impurity resolution depends on. The detail of how superficially porous particles sharpen closely eluting peptide peaks explains why they have become the default choice for this work.

Characterization and Quantification by Mass Spectrometry

Chromatography resolves species, but mass spectrometry confirms what they are. For GLP-1 agonists, electrospray ionization produces multiply charged envelopes that are deconvoluted to a zero-charge intact mass, establishing identity and flagging mass-shifted variants such as oxidation and deamidation products. Peptide mapping by LC-MS/MS then localizes modifications to specific residues, and high-resolution instruments separate isobaric and low-abundance impurities that lower-resolution detectors miss.

Quantification is a distinct discipline from identification. Accurate area integration depends on symmetrical, efficient peaks, which is precisely why column efficiency and method robustness feed directly into the reliability of a potency or purity result. The two activities, characterization and quantification, should be designed together rather than bolted on at the end.

Identification and quantification draw on different parts of the toolkit, and the orthogonal combination matters more than any single instrument. Intact mass, peptide mapping, and high-resolution detection each answer a different question and are strongest when used together. A closer look at building an orthogonal characterization and quantification workflow shows how the pieces fit.

Where Do GLP-1 Methods Most Often Fail?

Most GLP-1 method failures trace back to a small set of root causes: non-specific adsorption on metal surfaces producing tailing and lost sensitivity, gradients too steep to resolve critical pairs, insufficient column efficiency for trace impurities, and sample diluents that destabilize the peptide before it reaches the column. Because the consequences look similar, a tailing or missing impurity peak, diagnosing the actual cause is often the hardest part of the work.

The practical fix is usually a combination of lower-adsorption hardware, shallower gradients, higher-efficiency columns, and disciplined sample preparation, validated through robustness testing across instruments, column batches, and operators. Method transfer is where weak methods reveal themselves, so building robustness in from the start pays for itself.

The hardest part is usually diagnosis, because very different causes produce similar-looking symptoms on the chromatogram. A tailing peak might point to metal adsorption, a gradient that is too steep, or a sample degrading in the vial, and each calls for a different correction. Matching specific failure modes to their root causes and fixes is what turns a fragile method into one that survives transfer.

Regulatory Expectations for GLP-1 Related Substances

A point that is easy to get wrong: most marketed GLP-1 receptor agonists, including semaglutide and liraglutide, are synthetic peptides regulated through the new drug application and abbreviated new drug application pathways, not as biologics. That distinction shapes the entire analytical control strategy. Related-substance testing follows the impurity principles of ICH Q3A and Q3B, supplemented by FDA guidance specific to highly purified synthetic peptides, with characterization techniques borrowed from the protein world applied to the peptide itself.

In practice, this means specified and unspecified impurity thresholds, identity and immunogenicity justification for new impurities, and orthogonal methods to confirm impurity sameness against a reference listed drug. An analytical program that demonstrates command of this framework, rather than defaulting to a generic biologics or small-molecule template, is what earns reviewer and sponsor confidence.

This article was produced under Separation Science's AI Editorial Guidelines